DK2732289T3 - ANTIBODIES, KIT AND IN VITRO METHOD FOR DETECTING BETA AMYLOID OLIGOMERS - Google Patents

ANTIBODIES, KIT AND IN VITRO METHOD FOR DETECTING BETA AMYLOID OLIGOMERS Download PDF

Info

Publication number
DK2732289T3
DK2732289T3 DK12737445.2T DK12737445T DK2732289T3 DK 2732289 T3 DK2732289 T3 DK 2732289T3 DK 12737445 T DK12737445 T DK 12737445T DK 2732289 T3 DK2732289 T3 DK 2732289T3
Authority
DK
Denmark
Prior art keywords
ser
gly
antibody
thr
oligomers
Prior art date
Application number
DK12737445.2T
Other languages
Danish (da)
English (en)
Inventor
William F Goure
Alexander Mccampbell
Mary J Savage
Paul J Shughrue
Fubao Wang
Weirong Wang
Abigail L Wolfe
Ningyan Zhang
Wei-Qin Zhao
Renee C Gaspar
Min Xu
Original Assignee
Acumen Pharmaceuticals Inc
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/043866 external-priority patent/WO2012009442A2/en
Application filed by Acumen Pharmaceuticals Inc, Merck Sharp & Dohme filed Critical Acumen Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2732289T3 publication Critical patent/DK2732289T3/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
DK12737445.2T 2011-07-13 2012-07-09 ANTIBODIES, KIT AND IN VITRO METHOD FOR DETECTING BETA AMYLOID OLIGOMERS DK2732289T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161507332P 2011-07-13 2011-07-13
PCT/US2011/043866 WO2012009442A2 (en) 2010-07-14 2011-07-13 Anti-addl monoclonal antibody and uses thereof
PCT/US2012/045956 WO2013009703A2 (en) 2011-07-13 2012-07-09 Antibodies, kit and method for detecting amyloid beta oligomers

Publications (1)

Publication Number Publication Date
DK2732289T3 true DK2732289T3 (en) 2018-05-22

Family

ID=47506433

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12737445.2T DK2732289T3 (en) 2011-07-13 2012-07-09 ANTIBODIES, KIT AND IN VITRO METHOD FOR DETECTING BETA AMYLOID OLIGOMERS

Country Status (13)

Country Link
US (2) US20130052670A1 (https=)
EP (2) EP2732289B1 (https=)
JP (1) JP2014521089A (https=)
KR (1) KR20140072019A (https=)
CN (1) CN103782171B (https=)
AU (1) AU2012282825B2 (https=)
BR (1) BR112014000671A2 (https=)
CA (1) CA2840976A1 (https=)
DK (1) DK2732289T3 (https=)
ES (1) ES2666840T3 (https=)
MX (1) MX2014000480A (https=)
RU (1) RU2014105172A (https=)
WO (2) WO2013009667A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2699827T3 (es) 2009-06-17 2019-02-13 Biogen Ma Inc Composiciones y métodos para la modulación de corte y empalme de SMN2 en un sujeto
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
WO2014110291A1 (en) 2013-01-09 2014-07-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing in a subject
IL245703B (en) * 2013-11-20 2022-07-01 Univ Iowa Res Found Methods and compositions for treating amyloid deposits
EP3797780B1 (en) 2014-04-17 2022-09-14 Biogen MA Inc. Compositions and methods for modulation of smn2 splicing in a subject
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
MA41480A (fr) * 2014-10-17 2017-12-19 Glenmark Pharmaceuticals Sa Anticorps qui se lient au ccr6 et leurs utilisations
EP3341725B1 (en) * 2015-08-25 2021-08-18 Prothena Biosciences Limited Methods for detecting phosphorylated alpha-synuclein
EP3415912B1 (en) 2016-02-08 2023-03-29 Sysmex Corporation Analyte detection method and reagent kit for detecting analyte
US11198867B2 (en) 2016-06-16 2021-12-14 Ionis Pharmaceuticals, Inc. Combinations for the modulation of SMN expression
CN114026109A (zh) * 2019-07-05 2022-02-08 株式会社岛津制作所 β淀粉样蛋白的单克隆抗体、和使用该抗体的β淀粉样蛋白相关肽的测定方法
CN120505310A (zh) 2020-02-28 2025-08-19 Ionis制药公司 用于调节smn2的化合物和方法
WO2022270901A1 (ko) * 2021-06-25 2022-12-29 장재원 동적 형광 또는 x-선의 표준편차와 자기상관을 활용한 조기 진단 시스템
US20240358805A1 (en) * 2021-08-30 2024-10-31 The Brigham And Women's Hospital, Inc. Methods and materials to treat neurodegenerative disease
WO2024026413A2 (en) * 2022-07-27 2024-02-01 Durin Technologies, Inc. Early detection and monitoring of neurodegenerative diseases using a multi-disease diagnostic platform
CN117589996A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体的诊断用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665024A (en) 1984-10-01 1987-05-12 Becton, Dickinson And Company Fluorescent gram stain
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6082205A (en) 1998-02-06 2000-07-04 Ohio State University System and device for determining particle characteristics
DE60043165D1 (de) 1999-08-04 2009-11-26 Univ Southern California Globularer Aufbau vom Amyloid-beta- protein und deren Verwendungen
CN1871517A (zh) * 2002-02-19 2006-11-29 免疫公司 快速有效分离循环癌细胞的方法和试剂
US7807157B2 (en) 2004-02-20 2010-10-05 Intellect Neurosciences Inc. Monoclonal antibodies and use thereof
JP2008502880A (ja) * 2004-04-02 2008-01-31 メルク エンド カムパニー インコーポレーテッド アミロイド前駆体タンパク質又はβアミロイド断片に結合する物質を検出する方法及び結合化合物
US7572640B2 (en) 2004-09-28 2009-08-11 Singulex, Inc. Method for highly sensitive detection of single protein molecules labeled with fluorescent moieties
US7811563B2 (en) * 2004-10-25 2010-10-12 Northwestern University Anti-addl antibodies and uses thereof
US7731962B2 (en) 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
CN101291692A (zh) * 2005-10-21 2008-10-22 默克制药公司 抗addl单克隆抗体及其应用
US20090181359A1 (en) * 2007-10-25 2009-07-16 Lou Sheng C Method of performing ultra-sensitive immunoassays
CA2779565A1 (en) * 2009-11-24 2011-06-03 Probiodrug Ag Novel diagnostic method for the diagnosis of alzheimer's disease or mild cognitive impairment
WO2011151076A2 (en) * 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
EP2593475B1 (en) * 2010-07-14 2016-03-02 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42

Also Published As

Publication number Publication date
EP2732286A1 (en) 2014-05-21
WO2013009703A3 (en) 2013-03-21
WO2013009703A2 (en) 2013-01-17
EP2732286A4 (en) 2015-02-25
AU2012282825B2 (en) 2016-05-26
ES2666840T3 (es) 2018-05-08
CN103782171B (zh) 2016-12-14
KR20140072019A (ko) 2014-06-12
EP2732289A2 (en) 2014-05-21
AU2012282825A1 (en) 2014-01-16
CA2840976A1 (en) 2013-01-17
JP2014521089A (ja) 2014-08-25
RU2014105172A (ru) 2015-08-20
BR112014000671A2 (pt) 2017-02-14
US20130052670A1 (en) 2013-02-28
US20140120037A1 (en) 2014-05-01
MX2014000480A (es) 2014-06-23
WO2013009667A1 (en) 2013-01-17
CN103782171A (zh) 2014-05-07
WO2013009703A8 (en) 2014-01-23
EP2732289B1 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
DK2732289T3 (en) ANTIBODIES, KIT AND IN VITRO METHOD FOR DETECTING BETA AMYLOID OLIGOMERS
KR102716144B1 (ko) 신경퇴행을 검출하기 위한 분석
EP2731969B1 (en) Antibodies to phosphorylated tau aggregates
CA2584859C (en) Anti-addl antibodies and uses thereof
US9310383B2 (en) Antibodies, kit and method for detecting amyloid beta oligomers
EP2593475A2 (en) Anti-addl monoclonal antibody and uses thereof
CA3207924A1 (en) Methods for detecting neurofilament light chain in plasma and cerebrospinal fluid
KR20210068408A (ko) 가용성 bcma에 대한 항체
US12509505B2 (en) Anti Tau SVQIVYKPV epitope single domain antibody
WO2025137532A1 (en) Method for quantifying amyloid beta protofibril
WO2025260029A1 (en) Method for quantifying amyloid beta protofibril
WO2021032966A1 (en) Detection of a-beta oligomers
EA051573B1 (ru) АНТИТЕЛА К ПИРОГЛУТАМАТ-β-АМИЛОИДУ И ИХ ПРИМЕНЕНИЕ